Eidos Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced operating loss was USD 29.403 million compared to operating Income of USD 6.251 million a year ago. Net loss was USD 30.176 million compared to net income of USD 6.931 million a year ago. Basic loss per share from continuing operations was USD 0.79 compared to basic earnings per share from continuing operations of USD 0.19 a year ago. Diluted loss per share from continuing operations was USD 0.79 compared to diluted earnings per share from continuing operations of USD 0.18 a year ago. For the nine months, operating loss was USD 80.530 million compared to USD 21.127 million a year ago. Net loss was USD 81.849 million compared to USD 18.855 million a year ago. Basic loss per share from continuing operations was USD 2.14 compared to USD 0.52 a year ago.